The immune evasion roles of Staphylococcus aureus protein A and impact on vaccine development
While Staphylococcus aureus ( S. aureus ) bacteria are part of the human commensal flora, opportunistic invasion following breach of the epithelial layers can lead to a wide array of infection syndromes at both local and distant sites. Despite ubiquitous exposure from early infancy, the life-long ri...
Saved in:
Published in | Frontiers in cellular and infection microbiology Vol. 13; p. 1242702 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
27.09.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | While
Staphylococcus aureus
(
S. aureus
) bacteria are part of the human commensal flora, opportunistic invasion following breach of the epithelial layers can lead to a wide array of infection syndromes at both local and distant sites. Despite ubiquitous exposure from early infancy, the life-long risk of opportunistic infection is facilitated by a broad repertoire of
S. aureus
virulence proteins. These proteins play a key role in inhibiting development of a long-term protective immune response by mechanisms ranging from dysregulation of the complement cascade to the disruption of leukocyte migration. In this review we describe the recent progress made in dissecting
S. aureus
immune evasion, focusing on the role of the superantigen, staphylococcal protein A (SpA). Evasion of the normal human immune response drives the ability of
S. aureus
to cause infection, often recurrently, and is also thought to be a major hindrance in the development of effective vaccination strategies. Understanding the role of
S. aureus
virulence protein and determining methods overcoming or subverting these mechanisms could lead to much-needed breakthroughs in vaccine and monoclonal antibody development. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Reviewed by: Nevena Arsenovic-Ranin, University of Belgrade, Serbia; Hernan Felipe Peñaloza, Pontificia Universidad Católica de Chile, Chile Edited by: Marina T. Milenković, University of Belgrade, Serbia Present address: Simone Pecetta, Moderna Inc, Cambridge, MA, United States |
ISSN: | 2235-2988 2235-2988 |
DOI: | 10.3389/fcimb.2023.1242702 |